Portal de Periódicos da CAPES

Decreases in Inflammatory and Coagulation Biomarkers Levels in HIV-Infected Patients Switching from Enfuvirtide to Raltegravir: ANRS 138 Substudy

2013; Oxford University Press; Volume: 208; Issue: 6 Linguagem: Inglês

10.1093/infdis/jit280

1537-6613

Érika Ferrari Rafael da Silva, Isabelle Charreau, B. Gourmel, Samia Mourah, Issa Kalidi, B Guillon, Nathalie De Castro, François Caron, Joséphine Braun, Jean‐Michel Molina, A. Arulananthan, M. Barlot, A. Bouchibti, Joseph M. Braun, R. Chrestia-Blanchine, V. Eliette, F. Euphrasie, Valérie Foubert, Isabelle Fournier, B Guillon, Steven M. Leonardo, Vincent Meiffrédy, Emmanuel Moreau, A. Polaert, Pascal Ralaimazava,

HIV Research and Treatment

Stored plasma specimens from 164 participants in the ANRS 138 trial were analyzed to determine interleukin 6 (IL-6), high-sensitivity C-reactive protein (hsCRP), and D-dimer levels at baseline and weeks 24 and 48. These virologically suppressed, treatment-experienced patients were randomly assigned to undergo an immediate switch (IS) or a deferred switch (DS; at week 24) from an enfuvirtide-based antiretroviral therapy (ART) regimen to a raltegravir-based regimen. At week 24, a significant decrease from baseline was observed in the IS arm, compared with the DS arm, for IL-6 level (−30% vs +10%; P < .002), hsCRP level (−46% vs +15%; P < .0001), and D-dimer level (−40% vs +6%; P < .0001). At week 48, there was a reproducible decrease in levels of all biomarkers in the DS arm.